Klaus-Michael Debatin
Overview
Explore the profile of Klaus-Michael Debatin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
286
Citations
9718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mack T, Gianferri T, Niedermayer A, Debatin K, Meyer L, Muench V
Sci Rep
. 2024 Nov;
14(1):26390.
PMID: 39488607
MicroRNAs (miRNAs) play dual roles in acute lymphoblastic leukemia (ALL) as both tumor suppressors and oncogenes, and miRNA expression profiles can be used for patient risk stratification. Precise assessment of...
2.
Fulda S, Kuufer M, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin K
Oncogene
. 2024 Oct;
43(46):3417.
PMID: 39443727
No abstract available.
3.
Wichert M, Fortner C, Niedermayer A, Bender J, Enzenmuller S, Debatin K, et al.
Blood Adv
. 2024 Oct;
8(23):6035-6042.
PMID: 39368805
No abstract available.
4.
Eigemann J, Janda A, Schuetz C, Lee-Kirsch M, Schulz A, Hoenig M, et al.
J Clin Immunol
. 2024 Sep;
45(1):1.
PMID: 39264518
Purpose: Genetic hypomorphic defects in X chromosomal IKBKG coding for the NF-κB essential modulator (NEMO) lead to ectodermal dysplasia and immunodeficiency in males and the skin disorder incontinentia pigmenti (IP)...
5.
Fulda S, Kuufer M, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin K
Oncogene
. 2024 Sep;
43(46):3416.
PMID: 39242822
No abstract available.
6.
Enzenmuller S, Niedermayer A, Seyfried F, Muench V, Tews D, Rupp U, et al.
Cell Death Dis
. 2024 Jul;
15(7):475.
PMID: 38961053
Deregulated apoptosis signaling is characteristic for many cancers and contributes to leukemogenesis and treatment failure in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Apoptosis is controlled by different pro- and anti-apoptotic...
7.
Roos J, Zinngrebe J, Huber-Lang M, Lupu L, Schmidt M, Strobel H, et al.
Cell Death Dis
. 2024 Apr;
15(4):285.
PMID: 38653969
Despite advances in the treatment and care of severe physical injuries, trauma remains one of the main reasons for disability-adjusted life years worldwide. Trauma patients often suffer from disturbances in...
8.
Schneider M, Potthoff A, Karpel-Massler G, Schuss P, Siegelin M, Debatin K, et al.
Mol Oncol
. 2024 Apr;
18(12):2890-2905.
PMID: 38567664
In recent years, the discovery of functional and communicative cellular tumour networks has led to a new understanding of malignant primary brain tumours. In this review, the authors shed light...
9.
Ongemach E, Zerrinius D, Heimann P, Wirtz C, Debatin K, Westhoff M, et al.
Pharmaceuticals (Basel)
. 2024 Mar;
17(3).
PMID: 38543187
Glioblastoma, the most common and lethal primary adult brain tumor, cannot be successfully removed surgically due to its highly invasive nature. Therapeutically, approaches must be aimed at a systemic brain...
10.
Maier F, Schulz A, Furlan I, Felgentreff K, Jacobsen E, Sirin M, et al.
Clin Immunol
. 2024 Jan;
259:109891.
PMID: 38185266
For patients with inborn errors of immunity (IEI) and other inborn diseases, mixed donor chimerism is a well-accepted outcome of hematopoietic stem cell transplantation (HSCT). Cytoreductive chemotherapy for a secondary...